Tobin Schilke
CIK 1678984 · Chief Financial & Infra. Ofcr. · last filed 2026-09-01
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
RVNC price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
6055 LUSK BOULEVARD
SAN DIEGO, CA 92121
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Crinetics Pharmaceuticals, Inc. (CRNX) Delisted | Chief Financial & Infra. Ofcr. | 0 | $84.95 | $0 | -$266.3K | 5 | 2026-09-01 |
| Revance Therapeutics, Inc. (RVNC) Delisted | CFO | 0 | $3.65 | $0 | -$2.07M | 43 | 2025-02-06 |
| Achaogen, Inc. (AKAO) Delisted | Chief Financial Officer | 48,046 | — | — | -$100.1K | 8 | 2018-06-28 |
Recent Filings · Page 2 of 7
63 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-03-19 | Revance Therapeutics, Inc. (RVNC) Delisted | Mixed | −13,183 | -$67.5K | EDGAR |
| 2024-03-18 | — | Notice (144) | −9,500 | -$52.5K | EDGAR |
| 2024-03-04 | Revance Therapeutics, Inc. (RVNC) Delisted | Grant (A) | +17,447 | $0 | EDGAR |
| 2024-02-02 | Revance Therapeutics, Inc. (RVNC) Delisted | Grant (A) | +96,667 | $0 | EDGAR |
| 2024-01-03 | Revance Therapeutics, Inc. (RVNC) Delisted | Grant (A) | +434 | $3.2K | EDGAR |
| 2023-08-15 | Revance Therapeutics, Inc. (RVNC) Delisted | Mixed | +11,405 | -$212.1K | EDGAR |
| 2023-07-05 | Revance Therapeutics, Inc. (RVNC) Delisted | Mixed | −932 | -$30.6K | EDGAR |
| 2023-07-03 | — | Notice (144) | −1,701 | -$42.6K | EDGAR |
| 2023-06-05 | Revance Therapeutics, Inc. (RVNC) Delisted | Sell (S) | −3,201 | -$98.1K | EDGAR |
| 2023-06-02 | — | Notice (144) | −500 | -$15.5K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.